Luxturna™ (voretigene neparvovec-rzyl) – New orphan drug approval
December 19, 2017 – The FDA approved Spark Therapeutics’ Luxturna (voretigene neparvovec-rzyl), for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Download PDF
